Spero Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q3 2016 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Spero Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2016 to Q4 2024.
  • Spero Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$21.7M, a 143% decline year-over-year.
  • Spero Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$73.4M, a 442% decline year-over-year.
  • Spero Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$73.4M, a 442% decline from 2023.
  • Spero Therapeutics, Inc. annual Operating Income (Loss) for 2023 was $21.5M.
  • Spero Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$42.2M, a 52% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$73.4M -$21.7M -$72.3M -143% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-27
Q3 2024 -$1.1M -$18.6M -$16.7M -861% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $15.6M -$19.1M -$6.17M -47.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $21.7M -$14M +$245K +1.72% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $21.5M $50.5M +$24.6M +94.9% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-27
Q3 2023 -$3.13M -$1.93M +$9.9M +83.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$13M -$12.9M +$13.2M +50.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$26.2M -$14.2M +$16M +52.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$42.2M $25.9M +$53.4M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 -$95.6M -$11.8M +$10.7M +47.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$106M -$26.1M -$7.54M -40.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$98.8M -$30.2M -$10.8M -55.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$88M -$27.5M -$8.71M -46.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$79.3M -$22.5M -$3.5M -18.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$75.8M -$18.5M -$66K -0.36% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 -$75.7M -$19.4M +$3.42M +15% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$79.1M -$18.8M +$7.09M +27.4% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$86.2M -$19M -$1.04M -5.76% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$85.2M -$18.5M -$4.82M -35.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$80.3M -$22.8M -$17.1M -301% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$63.2M -$25.9M -$14.8M -134% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$48.4M -$18M -$7.05M -64.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$41.4M -$13.7M -$3.68M -36.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$37.7M -$5.7M +$5.12M +47.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 -$42.8M -$11.1M +$2.92M +20.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$45.7M -$10.9M -$969K -9.72% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-04
Q2 2018 -$44.8M -$9.97M +$194K +1.91% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$44.9M -$10.8M -$3.22M -42.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 -$41.7M -$14M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$9.97M -$2.05M -25.9% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 -$10.2M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$7.6M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q3 2016 -$7.91M Jul 1, 2016 Sep 30, 2016 10-Q 2017-12-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.